Slides on Key Decisions in HIV Care: ART Considerations With Coinfections

Learn key considerations when choosing ART for patients with coinfections including for patients with HBV/HIV and TB/HIV.
Daria Podlekareva, MD, PhD
Mark S. Sulkowski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.20 MB
Released: December 29, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)

Daria Podlekareva, MD, PhD Released: March 7, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

Prof Gail Matthews, MD, PhD Released: January 25, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Clinical Care Options (CCO) presents a woman’s perspective on her journey from a late HIV diagnosis to treatment, suppression, and searching for her purpose

person default Anonymous Patient Released: December 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings